Loading...
OTCM
IFTBF
Market cap60mUSD
Oct 07, Last price  
8.20USD
Name

Infant Bacterial Therapeutics AB

Chart & Performance

D1W1MN
OTCM:IFTBF chart
P/E
—
P/S
250,529.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.71%
Rev. gr., 5y
22.47%
Revenues
4k
-94.81%
0000162,000238,000000012,00077,0004,000
Net income
-137m
L+11.24%
-1,7050-6,747,000-20,624,000-38,106,000-36,156,000-40,607,000-47,045,000-72,310,000-45,404,000-65,094,000-123,068,000-136,905,000
CFO
-113m
L+11.77%
0-3,772,000-17,024,000-39,748,000-34,763,000-47,409,000-51,301,000-58,389,000-55,623,000-85,795,000-101,219,000-113,133,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.
URL
https://ibtherapeutics.com/
IPO date
Mar 29, 2016
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT